<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427412</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2013-134</org_study_id>
    <nct_id>NCT02427412</nct_id>
  </id_info>
  <brief_title>Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty</brief_title>
  <official_title>Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty - A Randomized, Prospective, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, prospective, placebo-controlled study which aims to evaluate the effect of
      combined intraarticular and intravenous Tranexamic acid on total blood loss following
      unilateral knee replacement versus only intravenous tranexamic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous (IV) Tranexamic acid is already well-established and well-documented regarding
      significant effect on reducing blood loss following knee replacement. A few studies more
      shown a similar effect of intraarticular (IA) injected Tranexamic acid into the knee joint at
      the end of surgery for knee replacement.

      In this study investigators therefore investigate the possible combined effect of added
      intraarticular tranexamic acid to conventional intravenous Tranexamic acid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total estimated blood loss</measure>
    <time_frame>24 hours surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total estimated blood loss</measure>
    <time_frame>2 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>90 days postoperative</time_frame>
    <description>90 days followup for thromboembolic complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>while hospitalized expected 3 days.</time_frame>
    <description>Estimate the extent of blood transfusions during admission and readmission in relation to the knee replacement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Blood Loss</condition>
  <condition>Postoperative Blood Loss</condition>
  <condition>Thromboembolic Complications</condition>
  <arm_group>
    <arm_group_label>IA Tranexamic acid + IV Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IA Saline Water + IV tranexamic Acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.</description>
    <arm_group_label>IA Tranexamic acid + IV Tranexamic Acid</arm_group_label>
    <other_name>Cyclokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline water</intervention_name>
    <description>30 ml of Saline water injected into the knee capsula at the end of surgery.</description>
    <arm_group_label>IA Saline Water + IV tranexamic Acid</arm_group_label>
    <other_name>NaCl water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.</description>
    <arm_group_label>IA Tranexamic acid + IV Tranexamic Acid</arm_group_label>
    <arm_group_label>IA Saline Water + IV tranexamic Acid</arm_group_label>
    <other_name>Cyklocapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  Unilateral knee replacement

          -  Must be able to give oral and written consent

        Exclusion Criteria:

          -  General Anesthetized

          -  Allergic to Tranexamic acid

          -  In treatment with the following anticoagulants: Adenosine diphosphate receptor
             inhibitors or vitamin K antagonist within in the last 5 days. Factor Xa inhibitor and
             thrombin inhibitor.

          -  Use of oral anticonceptive.

          -  Reduced kidney function (S-creatinine &gt; 120 micromol/L)

          -  Medicine or alcohol abuse

          -  Females with menstruation within the last 12 mounts.

          -  Any kind of cancer disease

          -  Rheumatoid arthritis

          -  Have participated in a clinical trial within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Husted, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Skovgaard Nielsen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Knee Arthroplasty</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>Thrombolic complication</keyword>
  <keyword>Total blood loss 24 h after ended surgery.</keyword>
  <keyword>Total blood loss 2 days after ended surgery.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
    <mesh_term>Exsanguination</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

